+96%

est. 2Y upside i

HealthcareSeries B

Rank

#468

Sector

Healthcare AI

Est. Liquidity

~3Y

Data Quality

Data: Medium

Causaly offers a solid equity opportunity with a 96% expected upside over 2 years, driven by strong product-market fit and a growing healthcare AI market.

Last updated: July 3, 2026

Bull (20%)+165%

Microsoft partnership drives category leadership; business triples revenue to $163M by Jun 2028 and multiple expands to 9x, yielding a $1.47B exit; net of 20% dilution, employee sees 165% upside.

Base (35%)+121%

Revenue grows to $163M with 7.5x exit multiple for $1.22B valuation; diluted 20% gives 121% return to employee.

Bear (45%)+47%

Growth slows to 35% in 2028, multiple compresses to 5x due to Big Tech competition, exit at $816M; after dilution, employee gains 47%.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

20%

Total preferred stock of $93M represents 20% of current valuation, creating a high overhang in downside scenarios.

Dilution Risk

high

With $93M raised and high burn rate, another dilutive round within 24 months is likely, estimated at 20% dilution.

Secondary Liquidity

limited

No active secondary market; liquidity expected only via IPO or acquisition in 3+ years.

Strategic Sales — 2 roles

Business Operations — 1 role

Product — 1 role

View all 7 open roles at Causaly →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Causaly's data — designed to show you've done your homework.

  • 1

    “How does Causaly's knowledge graph differ from OpenAI's GPT for biomedical research?”

  • 2

    “What is the revenue split between pharma and biotech customers?”

  • 3

    “Given the high competition, what is the plan to maintain a 2-year headstart?”

Community

Valuation Sentiment

Our model estimates +96% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.